Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1517455

Cover Image

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1517455

Global Pharmaceutical Suspension Market Size Study, by Type, by Indication, by End User, by Distribution Channel and Regional Forecasts 2022-2032

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (Enterprise License)
USD 6250

Add to Cart

The Global Pharmaceutical Suspension Market is valued approximately at USD 57.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.2% over the forecast period 2024-2032. Pharmaceutical suspension, a liquid dosage form with finely dispersed solid particles, offers a versatile drug delivery system for oral or parenteral administration. The suspended solid particles, often insoluble drugs, remain uniformly dispersed, enhancing stability and bioavailability, particularly for poorly soluble drugs. This formulation method not only eases administration and improves patient compliance but also allows for flexible dosage adjustments, making it suitable for a wide array of drug types and contributing to its extensive use in the pharmaceutical industry. Key players in the market, such as Pfizer Inc. and Merck & Co., Inc., continue to innovate and expand their product portfolios, driving market growth during the forecast period 2024-2032.

The market's robust growth trajectory is driven by the increasing prevalence of chronic diseases such as cancer and gastrointestinal disorders. For instance, the National Institute of Health reports a 23% prevalence of gastroesophageal reflux disease (GERD) among the elderly, highlighting the critical role of pharmaceutical suspensions in advanced drug delivery systems. Moreover, the demand for enhanced patient compliance and versatile administration methods propels market expansion. Positioned as a key component in evolving healthcare paradigms, pharmaceutical suspensions are vital in addressing various chronic medical conditions, reflecting a shift towards personalized treatment approaches. The pharmaceutical suspensions market is also bolstered by the rising geriatric population, necessitating targeted and localized drug delivery methods for chronic and acute medical conditions prevalent in this demographic. Additionally, advancements in research and development are leading to innovative formulations catering to specific medical needs, further driving market growth. However, the market faces challenges such as limited drug compatibility and manufacturing complexities, which elevate production costs and restrict market accessibility and affordability.

The key regions considered for the global pharmaceutical suspension market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. In 2023, North America was the largest regional market due to its advanced healthcare infrastructure and the presence of leading pharmaceutical manufacturers driving innovation. The United States and Canada have highly developed healthcare systems with significant investments in pharmaceutical research and development. Many of the world's leading pharmaceutical companies are headquartered in North America, driving innovation and production in the region. Moreover, North America is known for its substantial investment in research and development, leading to the development of advanced pharmaceutical formulations, including suspensions. Furthermore, the Asia-Pacific region is expected to grow at the fastest rate over the forecast period, driven by a rising geriatric population, increased prevalence of chronic disorders, and enhancements in healthcare infrastructure.

Major market players included in this report are:

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Bayer AG
  • Sanofi
  • Lupin
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Mylan N.V.
  • Johnson & Johnson

The detailed segments and sub-segment of the market are explained below:

By Type:

  • Oral
  • Parenteral
  • Others

By Indication:

  • Infectious Diseases
  • Cancer
  • Gastrointestinal
  • Neurological
  • Others

By End User:

  • Hospitals and Clinics
  • Home Care Settings
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Providers

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Pharmaceutical Suspension Market Executive Summary

  • 1.1. Global Pharmaceutical Suspension Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Type
    • 1.3.2. By Indication
    • 1.3.3. By End User
    • 1.3.4. By Distribution Channel
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Pharmaceutical Suspension Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Pharmaceutical Suspension Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rise in Chronic Diseases
    • 3.1.2. Growing Geriatric Population
    • 3.1.3. Advancements in R&D
  • 3.2. Market Challenges
    • 3.2.1. Limited Drug Compatibility
    • 3.2.2. Manufacturing Complexities
  • 3.3. Market Opportunities
    • 3.3.1. Increasing Generic Suspensions
    • 3.3.2. Cost-effective Healthcare Solutions
    • 3.3.3. Technological Innovations

Chapter 4. Global Pharmaceutical Suspension Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Pharmaceutical Suspension Market Size & Forecasts by Type 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Pharmaceutical Suspension Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Oral
    • 5.2.2. Parenteral
    • 5.2.3. Others

Chapter 6. Global Pharmaceutical Suspension Market Size & Forecasts by Indication 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Pharmaceutical Suspension Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Infectious Diseases
    • 6.2.2. Cancer
    • 6.2.3. Gastrointestinal
    • 6.2.4. Neurological
    • 6.2.5. Others

Chapter 7. Global Pharmaceutical Suspension Market Size & Forecasts by End User 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Pharmaceutical Suspension Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 7.2.1. Hospitals and Clinics
    • 7.2.2. Home Care Settings
    • 7.2.3. Others

Chapter 8. Global Pharmaceutical Suspension Market Size & Forecasts by Distribution Channel 2022-2032

  • 8.1. Segment Dashboard
  • 8.2. Global Pharmaceutical Suspension Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Drug Store and Retail Pharmacies
    • 8.2.3. Online Providers

Chapter 9. Global Pharmaceutical Suspension Market Size & Forecasts by Region 2022-2032

  • 9.1. North America Pharmaceutical Suspension Market
    • 9.1.1. U.S. Pharmaceutical Suspension Market
      • 9.1.1.1. Type breakdown size & forecasts, 2022-2032
      • 9.1.1.2. Indication breakdown size & forecasts, 2022-2032
      • 9.1.1.3. End User breakdown size & forecasts, 2022-2032
      • 9.1.1.4. Distribution Channel breakdown size & forecasts, 2022-2032
    • 9.1.2. Canada Pharmaceutical Suspension Market
      • 9.1.2.1. Type breakdown size & forecasts, 2022-2032
      • 9.1.2.2. Indication breakdown size & forecasts, 2022-2032
      • 9.1.2.3. End User breakdown size & forecasts, 2022-2032
      • 9.1.2.4. Distribution Channel breakdown size & forecasts, 2022-2032
  • 9.2. Europe Pharmaceutical Suspension Market
    • 9.2.1. UK Pharmaceutical Suspension Market
    • 9.2.2. Germany Pharmaceutical Suspension Market
    • 9.2.3. France Pharmaceutical Suspension Market
    • 9.2.4. Spain Pharmaceutical Suspension Market
    • 9.2.5. Italy Pharmaceutical Suspension Market
    • 9.2.6. Rest of Europe Pharmaceutical Suspension Market
  • 9.3. Asia-Pacific Pharmaceutical Suspension Market
    • 9.3.1. China Pharmaceutical Suspension Market
    • 9.3.2. India Pharmaceutical Suspension Market
    • 9.3.3. Japan Pharmaceutical Suspension Market
    • 9.3.4. Australia Pharmaceutical Suspension Market
    • 9.3.5. South Korea Pharmaceutical Suspension Market
    • 9.3.6. Rest of Asia Pacific Pharmaceutical Suspension Market
  • 9.4. Latin America Pharmaceutical Suspension Market
    • 9.4.1. Brazil Pharmaceutical Suspension Market
    • 9.4.2. Mexico Pharmaceutical Suspension Market
    • 9.4.3. Rest of Latin America Pharmaceutical Suspension Market
  • 9.5. Middle East & Africa Pharmaceutical Suspension Market
    • 9.5.1. Saudi Arabia Pharmaceutical Suspension Market
    • 9.5.2. South Africa Pharmaceutical Suspension Market
    • 9.5.3. Rest of Middle East & Africa Pharmaceutical Suspension Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. Pfizer Inc.
      • 10.3.1.1. Key Information
      • 10.3.1.2. Overview
      • 10.3.1.3. Financial (Subject to Data Availability)
      • 10.3.1.4. Product Summary
      • 10.3.1.5. Market Strategies
    • 10.3.2. Merck & Co., Inc.
    • 10.3.3. AstraZeneca plc
    • 10.3.4. Eli Lilly and Company
    • 10.3.5. Bayer AG
    • 10.3.6. Sanofi
    • 10.3.7. Lupin
    • 10.3.8. Glenmark Pharmaceuticals Limited
    • 10.3.9. Novartis AG
    • 10.3.10. Teva Pharmaceutical Industries Limited
    • 10.3.11. Sun Pharmaceutical Industries Ltd.
    • 10.3.12. Cipla Inc.
    • 10.3.13. Dr. Reddy's Laboratories Ltd.
    • 10.3.14. Mylan N.V.
    • 10.3.15. Johnson & Johnson

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!